Multiple control plasma samples were analysed as follows: plasma treated with the reaction mixture without DHM; plasma treated with monocrotaline alone; and plasma treated with the carrier solvent, DMF.
Multiple plasma and urine samples were positive for both AdV and BKV.
In contrast, instead of multiple bands the plasma samples showed 25-kDa OPN form alone.
This system consists of multiplex beads and detection antibodies designed to quantitate, in pg/ml, multiple cytokines in plasma samples.
Except for FeO x I activity measurement, where fresh serum samples were used, multiple aliquots of plasma samples were stored at −80°C until assay time for norepinephrine, BNP, free malondialdehyde (MAD), total nitrated proteins, and Cp.
Multiplexing represents a powerful platform for the qualitative and quantitative assessment of cancer biomarker signatures, giving the opportunity for sensitive and specific detection of multiple oncoproteins in plasma samples, providing a suite of biomarkers with potential for use as stage-specific indicators of CRC progression.
Only a subgroup of patients underwent multiple samplings, thus paired plasma samples were available for 25 patients at d1 and at d15, for 24 patients at d57, for 21 patients at d155 and for 16 patients at the time of PD.
Multiple rumen fluid and blood plasma samples were collected and analyzed for pH and rumen fluid endotoxin and for concentrations of glucose, insulin, cholesterol, β-hydroxybutyrate (BHBA), nonesterified fatty acids (NEFA), and lactate in the plasma.
